Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05165485 · ClinicalTrials.gov registry record · Phase 4
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
A Phase 4 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 404
- Enrollment target
NCT05165485 is a Phase 4 study that has completed, run by Theravance Biopharma. The registered enrollment target is 404 participants.
The verdict
NCT05165485, a Phase 4 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 404 participants
- Enrollment target
Study Summary
Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
Interventions
- DRUG Tiotropium
- DRUG Revefenacin
- DRUG Revefenacin Placebo
- DRUG Tiotropium Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2022-01-07 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05165485
The ClinicalTrials.gov registry entry for NCT05165485 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tiotropium is the first listed.
NCT05165485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05165485 about?
NCT05165485 is a clinical study titled "Phase 4 COPD and Suboptimal Inspiratory Flow Rate". Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
What is the current status of trial NCT05165485?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 404 participants. The study started on 2022-01-07. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT05165485?
The interventions under investigation include: Tiotropium (DRUG), Revefenacin (DRUG), Revefenacin Placebo (DRUG), Tiotropium Placebo (DRUG).
Who is sponsoring clinical trial NCT05165485?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.